Immune Modulators for Peripheral Nerve Regeneration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating peripheral nerve injuries, particularly those requiring surgical intervention, are inadequate in bridging nerve gaps longer than 2-3 cm and do not significantly enhance or improve the quality of nerve regeneration, leading to suboptimal recovery and permanent paralysis in many cases.
Innovation Solution
The use of CXCR4 antagonists, STAT3 activators, and nitric oxide increasing agents, alone or in combination, to promote nerve growth and regeneration, potentially with the aid of physical support structures like conduits made from materials such as poly-lactide acid or silicone, and administration of nerve growth factors like NGF, BDNF, and GDNF, to facilitate regeneration across critical gaps.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional surgical intervention is used for peripheral nerve injuries, then the procedure is straightforward and commercially available products can bridge short nerve defects, but the method is inadequate for bridging nerve gaps longer than 2-3 cm and does not significantly enhance nerve regeneration quality
Solution Approach 1:
The patent applies parameter changes by modifying the chemical and biological environment through immune modulators (CXCR4 antagonists, STAT3 activators, nitric oxide increasing agents) to enhance nerve regeneration. These agents change the physiological parameters of the injury site, promoting axonal growth and improving regeneration quality across gaps of varying lengths, thereby resolving the contradiction between reliability and adaptability.
2Length of stationary object
If exogenous materials are used to bridge nerve gaps, then short nerve defects can be bridged, but the method fails to bridge critical gaps of 3 cm or more
Solution Approach 1:
The patent uses immune modulators as intermediaries to facilitate nerve regeneration across critical gaps. These agents (CXCR4 antagonists, STAT3 activators, nitric oxide increasing agents) mediate the interaction between the injury site and regenerating axons, creating a favorable microenvironment that enables bridging of gaps 3 cm or more while maintaining high regeneration quality, thus resolving the contradiction between gap length and regeneration reliability.
3Productivity
If no immune modulation is applied, then the treatment approach is simple, but nerve regeneration is limited and suboptimal recovery occurs
Solution Approach 1:
The patent applies preliminary action by administering immune modulators before and during the nerve regeneration process. These agents are given in advance to prepare the injury microenvironment, reduce inflammation, and promote axonal growth factors, thereby accelerating nerve regeneration speed. The multi-agent protocol (CXCR4 antagonists, STAT3 activators, nitric oxide increasing agents) systematically addresses multiple aspects of regeneration, resolving the contradiction between productivity and complexity.
Data Source
AI summary
The present disclosure describes the use of immune modulators to promote nerve growth and regeneration, particularly in the context of nerve deficit stemming from trauma and disease. In particular, the disclosure provides for the use of CXCR4 antagonsists, STAT3 activators, and an agent that increase nitric oxide, alone or in combination, to treat nerve deficit conditions.